Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Cel-Sci Corp

(AMEX: CVM)
Add to Portfolio
+0.33 (+2.96%)
as of Apr 7, 2020

Last 11.49
Change +0.33 (+2.96%)
Open 11.79
Prev. Close 11.16
Today's Range
11.22
11.90
52wk Range
3.69
17.80
Volume 442747
Avg Volume 768710
Sector SIC-2836 Biological Products, (No Disgnostic Substanc

Perfomance Comparison

Name Today 3-Month 1-Year
CVM +2.96% -13.35% +108.91%
DJIA -0.12% -20.61% -14.27%
S&P 500 -0.16% -18.01% -8.07%

Key Statistics

Annual EPS -0.88
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 357620
Weighted Alpha +114.80
Standard Deviation +0.35
Profit Margin -3643.62%
Beta 2.32

Growth Rates

YTD +25.57%
1-Year +94.43%
3-Year +346.40%
5-Year -52.00%
10-Year -93.71%

Opinion

Sell Hold Buy

Recent Headlines

CEL-SCI Announces Change of Location to 2020 Annual

BusinessWire via COMTEX - Mon Mar 30, 04:05PM EDT
CEL-SCI Corporation (NYSE American: CVM), announced today that the location of its 2020 Annual Meeting of Shareholders will be changed and a virtual format via a live online webcast will be added. The annual stockholders meeting, (full story)
CVM: 11.49 (+0.33)

CEL-SCI Announces the Closing of Its $7.7 Million

BusinessWire via COMTEX - Thu Mar 26, 11:05AM EDT
CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced the closing of the offering of 630,500 shares of its common stock at a price of $12.22 per share, for total gross proceeds of approximatel(full story)
CVM: 11.49 (+0.33)

CEL-SCI Increases Previously Announced Bought Deal to

BusinessWire via COMTEX - Tue Mar 24, 09:25AM EDT
CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that, due to demand, the underwriter has agreed to increase the size of its previously announced offering and purchase on a firm com(full story)
CVM: 11.49 (+0.33)

CEL-SCI Announces Bought Deal Offering

BusinessWire via COMTEX - Mon Mar 23, 09:46PM EDT
CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced today that it has entered into an underwriting agreement with Aegis Capital Corp. under which the underwriter has agreed to purchase(full story)
CVM: 11.49 (+0.33)

CEL-SCI to Develop LEAPS COVID-19 Immunotherapy in

BusinessWire via COMTEX - Mon Mar 23, 09:23AM EDT
CEL-SCI Corporation (NYSE American: CVM) announced today it has signed a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. CEL-SCI's immunotherapy (full story)
CVM: 11.49 (+0.33)